Jae Yoon Jeon

Gilteritinib Inhibits Glutamine Uptake and Utilization in <i>FLT3</i>-ITD–Positive AML

Megan E. Zavorka Thomas, Xiyuan Lu, Zahra Talebi et al. · Molecular Cancer Therapeutics · 2021 · 45 citations · Full text

Medicine, Oncology, Pharmacology +13

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

Christina D. Drenberg, Anang A. Shelat, Jinjun Dang et al. · Nature Communications · 2019 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

Jae Yoon Jeon, Qiuhong Zhao, Daelynn R. Buelow et al. · Investigational New Drugs · 2019 · 40 citations · Full text

Medicine, Oncology, Pharmacology +13

TP-0903 is active in models of drug-resistant acute myeloid leukemia

Jae Yoon Jeon, Daelynn R. Buelow, Dominique A. Garrison et al. · JCI Insight · 2020 · 33 citations · Full text

Medicine, Oncology, Pharmacology +13

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

Ola A. Elgamal, Abeera Mehmood, Jae Yoon Jeon et al. · Journal of Hematology & Oncology · 2020 · 20 citations · Full text

Medicine, Oncology, Pharmacology +15